Charles M. Diker Sells 14,897 Shares of Cantel Medical Corp. (CMN) Stock
Cantel Medical Corp. (NYSE:CMN) Chairman Charles M. Diker sold 14,897 shares of the stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $78.76, for a total transaction of $1,173,287.72. Following the completion of the transaction, the chairman now owns 3,190,111 shares in the company, valued at approximately $251,253,142.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Cantel Medical Corp. (NYSE:CMN) opened at 75.38 on Friday. The stock has a 50 day moving average of $77.74 and a 200 day moving average of $71.21. Cantel Medical Corp. has a 52 week low of $54.93 and a 52 week high of $81.63. The company has a market cap of $3.12 billion, a PE ratio of 52.42 and a beta of 1.59.
Cantel Medical Corp. (NYSE:CMN) last announced its earnings results on Thursday, September 29th. The company reported $0.48 EPS for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.11. The business earned $179 million during the quarter. Cantel Medical Corp. had a net margin of 9.02% and a return on equity of 16.70%. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.39 earnings per share. Equities research analysts predict that Cantel Medical Corp. will post $1.98 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the company. Henderson Group PLC increased its position in shares of Cantel Medical Corp. by 51.1% in the second quarter. Henderson Group PLC now owns 680,016 shares of the company’s stock worth $46,737,000 after buying an additional 230,084 shares in the last quarter. Riverhead Capital Management LLC raised its stake in shares of Cantel Medical Corp. by 2,688.4% in the second quarter. Riverhead Capital Management LLC now owns 193,853 shares of the company’s stock worth $12,312,000 after buying an additional 186,901 shares during the last quarter. Neuberger Berman Group LLC raised its stake in shares of Cantel Medical Corp. by 23.1% in the second quarter. Neuberger Berman Group LLC now owns 952,754 shares of the company’s stock worth $65,483,000 after buying an additional 179,096 shares during the last quarter. BlackRock Fund Advisors raised its stake in shares of Cantel Medical Corp. by 5.9% in the second quarter. BlackRock Fund Advisors now owns 2,414,895 shares of the company’s stock worth $165,976,000 after buying an additional 135,506 shares during the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of Cantel Medical Corp. by 181.1% in the second quarter. Citadel Advisors LLC now owns 190,518 shares of the company’s stock worth $13,094,000 after buying an additional 122,745 shares during the last quarter. Institutional investors and hedge funds own 81.60% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Benchmark Co. set a $83.00 price objective on shares of Cantel Medical Corp. and gave the stock a “buy” rating in a research note on Saturday, October 1st. Needham & Company LLC assumed coverage on shares of Cantel Medical Corp. in a research note on Wednesday, August 24th. They issued a “hold” rating on the stock.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.